The company is expanding its digital healthcare platform into new areas including labs, cancer screening, menopause care, and international markets. However, it faces significant headwinds from a patent infringement lawsuit by Novo Nordisk over compounded weight loss drugs, along with investigations by the FDA and SEC regarding its GLP-1 medication practices. The stock has declined sharply over the past year amid these regulatory and legal challenges, even as the company pursues a broader telehealth growth strategy.